一分钟看懂
这是一项关于Bladder Adenocarcinoma的II 期研究，登记的药物或干预包括Biospecimen Collection；Bone Scan；Cabozantinib S-malate；Computed Tomography；Echocardiography Test；Ipilimumab；Magnetic Resonance Imaging；Nivol，当前状态为招募中。登记地点显示中国Birmingham、Anchorage、Kingman、Phoenix等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Biospecimen Collection；Bone Scan；Cabozantinib S-malate；Computed Tomography；Echocardiography Test；Ipilimumab；Magnetic Resonance Imaging；Nivolumab；Positron Emission Tomography · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- University of Alabama at Birmingham Cancer Center · Birmingham
- Anchorage Associates in Radiation Medicine · Anchorage
- Anchorage Radiation Therapy Center · Anchorage
- Alaska Breast Care and Surgery LLC · Anchorage
- Alaska Oncology and Hematology LLC · Anchorage
- Alaska Women's Cancer Care · Anchorage
- Anchorage Oncology Centre · Anchorage
- Katmai Oncology Group · Anchorage
- Providence Alaska Medical Center · Anchorage
- Kingman Regional Medical Center · Kingman
- Cancer Center at Saint Joseph's · Phoenix
- Mayo Clinic Hospital in Arizona · Phoenix
- Mayo Clinic in Arizona · Scottsdale
- University of Arizona Cancer Center-Orange Grove Campus · Tucson
- Banner University Medical Center - Tucson · Tucson
- University of Arizona Cancer Center-North Campus · Tucson
- Mercy Hospital Fort Smith · Fort Smith
- CHI Saint Vincent Cancer Center Hot Springs · Hot Springs
- Mission Hope Medical Oncology - Arroyo Grande · Arroyo Grande
- PCR Oncology · Arroyo Grande
- Providence Saint Joseph Medical Center/Disney Family Cancer Center · Burbank
- Community Cancer Institute · Clovis
- University Oncology Associates · Clovis
- Epic Care-Dublin · Dublin
- Bay Area Breast Surgeons Inc · Emeryville
- Epic Care Partners in Cancer Care · Emeryville
- Marin Cancer Care Inc · Greenbrae
- Keck Medicine of USC Koreatown · Los Angeles
- Los Angeles General Medical Center · Los Angeles
- USC / Norris Comprehensive Cancer Center · Los Angeles
公开的入选条件
- * Metastatic disease defined as new or progressive lesions on cross-sectional imaging or bone scan. Patients must have at least:
- One measurable site of disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
- One bone lesion on bone scan (tec99 or sodium fluoride \[NaF\] PET/CT, CT or MRI) for the bone-only cohort.
- Histologically confirmed diagnosis of one of the following metastatic cohorts:
- Small cell/ neuroendocrine carcinoma of the bladder (Cohort A)- All urothelial carcinomas with any amount of neuroendocrine differentiation (including small cell differentiation) will be included. If the tumor is purely neuroendocrine, metastasis from another
- Adenocarcinoma of the bladder, or urachal adenocarcinoma, or bladder/urethra clear cell adenocarcinoma (Cohort B)
- must be pure (per World Health Organization \[WHO\] definition), (i.e. urothelial carcinoma with glandular differentiation is not considered a pure adenocarcinoma
- Squamous cell carcinoma of the bladder (Cohort C)
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT03866382；登记信息更新于 2026-09-16。